Jonathan Cebon

Jonathan Cebon

UNVERIFIED PROFILE

Are you Jonathan Cebon?   Register this Author

Register author
Jonathan Cebon

Jonathan Cebon

Publications by authors named "Jonathan Cebon"

Are you Jonathan Cebon?   Register this Author

100Publications

10408Reads

43Profile Views

A distinct pre-treatment immune gene signature in lentigo maligna is associated with imiquimod response.

J Invest Dermatol 2019 Sep 30. Epub 2019 Sep 30.

Victorian Melanoma Service, Alfred Hospital; School of Public Health and Preventive Medicine, Monash University.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jid.2019.07.725DOI Listing
September 2019

Genomic Analysis of Circulating Tumor DNA Using a Melanoma-Specific UltraSEEK Oncogene Panel.

J Mol Diagn 2019 May 5;21(3):418-426. Epub 2019 Feb 5.

Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15251578183023
Publisher Site
http://dx.doi.org/10.1016/j.jmoldx.2018.12.001DOI Listing
May 2019

Real-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma.

Asia Pac J Clin Oncol 2019 Feb 13;15(1):26-30. Epub 2018 Nov 13.

Department of Medical Oncology, Canberra Region Cancer Centre, The Canberra Hospital, ACT, Australia.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ajco.13100
Publisher Site
http://dx.doi.org/10.1111/ajco.13100DOI Listing
February 2019

Association of good oncological response to therapy with the development of rheumatic immune-related adverse events following PD-1 inhibitor therapy.

Int J Rheum Dis 2019 Feb 22;22(2):297-302. Epub 2018 Nov 22.

Department of Rheumatology, Austin Health, Melbourne, VIC, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1756-185X.13444DOI Listing
February 2019

Perspective: cancer vaccines in the era of immune checkpoint blockade.

Authors:
Jonathan Cebon

Mamm Genome 2018 12 16;29(11-12):703-713. Epub 2018 Nov 16.

Cancer Immunobiology Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, Australia.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00335-018-9786-z
Publisher Site
http://dx.doi.org/10.1007/s00335-018-9786-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267701PMC
December 2018

Delayed Autoimmune Toxicity Occurring Several Months After Cessation of Anti-PD-1 Therapy.

Oncologist 2018 07 17;23(7):849-851. Epub 2018 Apr 17.

Medical Oncology Unit, Austin Health, Melbourne, Victoria, Australia

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2017-0531DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058335PMC
July 2018

Characterising the phenotypic evolution of circulating tumour cells during treatment.

Nat Commun 2018 04 16;9(1):1482. Epub 2018 Apr 16.

Centre for Personalised Nanomedicine, Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Brisbane, QLD, 4072, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-018-03725-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5902511PMC
April 2018

Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.

J Clin Oncol 2018 03 9;36(7):667-673. Epub 2017 Oct 9.

Georgina V. Long, University of Sydney, and Royal North Shore Hospital; Richard Kefford, Macquarie University, Sydney, and Westmead Hospital, Westmead, New South Wales; Jonathan Cebon, Ludwig Institute for Cancer Research, Melbourne, Victoria, Australia; Zeynep Eroglu, Moffitt Cancer Center, Tampa, FL; Jeffrey Infante, Tennessee Oncology; Douglas B. Johnson, Vanderbilt-Ingram Cancer Center, Nashville, TN; Sapna Patel, The University of Texas MD Anderson Cancer Center, Houston, TX; Adil Daud, University of California, San Francisco, San Francisco; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles, CA; Rene Gonzalez, University of Colorado, Denver, CO; Lynn Schuchter, University of Pennsylvania, Philadelphia, PA; William Sharfman, Sidney Kimmel Cancer Center, Baltimore, MD; Robert McWilliams, Mayo Clinic, Rochester, MN; Mario Sznol, Yale University, New Haven, CT; Suman Redhu, Eduard Gasal, and Bijoyesh Mookerjee, Novartis, East Hanover, NJ; Jeffrey Weber, New York University Langone Medical Center, New York, NY; and Keith T. Flaherty, Dana-Farber/Harvard Cancer Center, Boston, MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.74.1025
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.74.1025DOI Listing
March 2018

Divergent T-cell receptor recognition modes of a HLA-I restricted extended tumour-associated peptide.

Nat Commun 2018 03 12;9(1):1026. Epub 2018 Mar 12.

Infection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC, 3800, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-018-03321-wDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5847591PMC
March 2018

Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.

J Clin Oncol 2017 Dec 15;35(34):3815-3822. Epub 2017 Sep 15.

Mario Sznol, Yale Comprehensive Cancer Center, New Haven, CT; Pier Francesco Ferrucci, Istituto Europeo di Oncologia, Milan; Massimo Guidoboni, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy; David Hogg, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Michael B. Atkins, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC; Pascal Wolter, University Hospitals Leuven, Leuven, Belgium; Celeste Lebbé, Université Paris Diderot, Paris; Luc Thomas, Centre Hospitalier Lyon-Sud, Pierre-Bénite, France; John M. Kirkwood, Hillman Cancer Center, Pittsburgh, PA; Jacob Schachter, Sheba Medical Center, Ramat Gan, Israel; Gregory A. Daniels, University of California San Diego, Moores Cancer Center, La Jolla, CA; Jessica Hassel, University Hospital, Heidelberg, Germany; Jonathan Cebon, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria; Winald Gerritsen, University of Queensland, St Lucia; Victoria Atkinson, Gallipoli Medical Research Foundation, Greenslopes; Victoria Atkinson, Princess Alexandra Hospital, Brisbane, Queensland, Australia; Winald Gerritsen, Radboud University Medical Center, Nijmegen, the Netherlands; John McCaffrey, Irish Clinical Oncology Research Group, Dublin; Derek Power, Irish Clinical Oncology Research Group, Cork, Ireland; Dana Walker, Rafia Bhore, and Joel Jiang, Bristol-Myers Squibb, Princeton, NJ; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; and Jedd D. Wolchok, Parker Institute and Ludwig Center at Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.72.1167DOI Listing
December 2017

Intercellular Resistance to BRAF Inhibition Can Be Mediated by Extracellular Vesicle-Associated PDGFRβ.

Neoplasia 2017 Nov 28;19(11):932-940. Epub 2017 Sep 28.

Olivia Newton-John Cancer Research Institute, Level 5 Olivia Newton-John Cancer and Wellness Centre, Austin Health, Studley Road, Heidelberg, VIC 3084, Australia; School of Cancer Medicine, La Trobe University, Heidelberg, VIC 3084, Heidelberg.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neo.2017.07.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678363PMC
November 2017

Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.

Eur J Cancer 2017 11 4;86:115-124. Epub 2017 Oct 4.

Olivia Newton-John Cancer Research Institute, Austin Health, School of Cancer Medicine, La Trobe University, 145 Studley Road, Heidelberg VIC 3084, Melbourne, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.08.032DOI Listing
November 2017

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

N Engl J Med 2017 10 11;377(14):1345-1356. Epub 2017 Sep 11.

From the Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (J.D.W., M.A.P., M.K.C.); Oncology Institute of Veneto Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padua (V.C.-S.), European Institute of Oncology, Milan (P.F.F.), Center for Immuno-Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena (M.M.), the Immunotherapy and Somatic Cell Therapy Unit, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (M.G.), and Istituto Nazionale Tumori Fondazione Pascale, Naples (P.A.A.) - all in Italy; University of Colorado, Denver (R.G.); Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland (P.R.); Aix-Marseille University, Hôpital de la Timone, Marseille (J.-J.G.), and Assistance Publique-Hôpitaux de Paris, Dermatology and Centres d'Investigation Clinique, INSERM Unité 976, Hôpital Saint-Louis, Université Paris Diderot, Paris (C.L.) - both in France; Texas Oncology-Baylor Cancer Center, Dallas (C.L.C.); University of Michigan, Ann Arbor (C.D.L.); the College of Medicine, Swansea University, Swansea (J.W.), and Royal Marsden NHS Foundation Trust, London (J.L.) - both in the United Kingdom; the Department of Dermatology, University of Essen, Essen, and the German Cancer Consortium, Heidelberg - both in Germany (D.S.); Cross Cancer Institute, Edmonton, AB (M.S.), and Princess Margaret Cancer Centre, Toronto (D.H.) - both in Canada; Universitäts Spital, Zurich, Switzerland (R.D.); Tasman Oncology Research, Southport Gold Coast, QLD (A.H.), Crown Princess Mary Cancer Centre, Melanoma Institute Australia, University of Sydney (M.S.C.), and Melanoma Institute Australia, University of Sydney, and Royal North Shore and Mater Hospitals (G.V.L.), Sydney, and Peter MacCallum Cancer Centre (G.M.) and the Olivia Newton-John Cancer Research Institute, University of Melbourne (J.C.), Melbourne, VIC - all in Australia; Netherlands Cancer Institute, Amsterdam (J.H.); University Hospitals Leuven, KU Leuven, Leuven, Belgium (O.B.); General University Hospital Gregorio Marañón, Madrid (I.M.-R.); Northwestern University, Chicago (J.S.); Bristol-Myers Squibb, Princeton, NJ (D.W., L.R., R.B.); and the Dana-Farber Cancer Institute, Boston (F.S.H.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1709684DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706778PMC
October 2017

Systems analysis identifies miR-29b regulation of invasiveness in melanoma.

Mol Cancer 2016 11 16;15(1):72. Epub 2016 Nov 16.

Department of Medicine, University of Melbourne, Parkville, VIC, 3010, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12943-016-0554-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5112703PMC
November 2016

Altered Expression and Splicing of ESRP1 in Malignant Melanoma Correlates with Epithelial-Mesenchymal Status and Tumor-Associated Immune Cytolytic Activity.

Cancer Immunol Res 2016 06 4;4(6):552-61. Epub 2016 Apr 4.

Ludwig Collaborative Laboratory, Johns Hopkins University School of Medicine, Baltimore, Maryland. Regeneron Pharmaceuticals Inc., Tarrytown, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-15-0255DOI Listing
June 2016

Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.

J Clin Oncol 2016 Mar 25;34(8):871-8. Epub 2016 Jan 25.

Georgina V. Long, Melanoma Institute Australia; The University of Sydney; Richard F. Kefford, Melanoma Institute Australia; The University of Sydney; Macquarie University, Sydney; Westmead Hospital, Westmead; Jonathan Cebon, Austin Health, Melbourne, Victoria, Australia; Jeffrey S. Weber and Ragini Kudchadkar, Moffitt Cancer Center, Tampa, FL; Jeffrey R. Infante and Howard A. Burris III, Sarah Cannon Research Institute/Tennessee Oncology; Kevin B. Kim, California Pacific Medical Center; Adil Daud, Alain Algazi, University of California, San Francisco, San Francisco; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles, CA; Rene Gonzalez, Karl Lewis, University of Colorado; Gerald S. Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO; Jeffrey A. Sosman, Igor Puzanov, Vanderbilt University Medical Center, Nashville, TN; Lynn Schuchter, University of Pennsylvania Abramson Cancer Center; Nageatte Ibrahim, Elizabeth Cunningham, Merck; Peng Sun, Amy S. Kline, Heather Del Buono, Diane Opatt McDowell, GlaxoSmithKline, Philadelphia, PA; Donald Lawrence and Kiran Patel, Incyte Corporation, Wilmington, DE; and Keith T. Flaherty, Massachusetts General Hospital Cancer Center, Boston, MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2015.62.9345
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.62.9345DOI Listing
March 2016

Mycoplasma Infection Alters Cancer Stem Cell Properties in Vitro.

Stem Cell Rev Rep 2016 Feb;12(1):156-61

Ludwig Institute for Cancer Research, Austin Hospital, Studley Road, Heidelberg, VIC, 3084, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12015-015-9630-8DOI Listing
February 2016

Mismatch in epitope specificities between IFNγ inflamed and uninflamed conditions leads to escape from T lymphocyte killing in melanoma.

J Immunother Cancer 2016 16;4:10. Epub 2016 Feb 16.

School of Cancer Medicine, La Trobe University, Melbourne, VIC 3086 Australia ; Olivia Newton-John Cancer Research Institute, Level 5 ONJCWC, 145 Studley Road, Heidelberg, VIC 3084 Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-016-0111-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4754849PMC
February 2016

Capture and On-chip analysis of Melanoma Cells Using Tunable Surface Shear forces.

Sci Rep 2016 Jan 27;6:19709. Epub 2016 Jan 27.

Centre for Personalised NanoMedicine, Australian Institute for Bioengineering and Nanotechnology, University of Queensland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/srep19709DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4728558PMC
January 2016

Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma.

Clin Cancer Res 2015 Dec 22;21(23):5222-34. Epub 2015 Jul 22.

Medical Oncology, Austin Health, Austin Hospital, Heidelberg, Victoria, Australia. Ludwig Institute for Cancer Research, Austin Branch, Heidelberg, Victoria, Australia. Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia. School of Cancer Medicine, La Trobe University, Heidelberg, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-0393DOI Listing
December 2015

Tumour procurement, DNA extraction, coverage analysis and optimisation of mutation-detection algorithms for human melanoma genomes.

Pathology 2015 Dec;47(7):683-93

1Melanoma Institute Australia, North Sydney, NSW 2Sydney Medical School, The University of Sydney, Camperdown, NSW 3Immunogenomics Laboratory, Australian National University, Canberra, ACT 4Oncogenomics Laboratory, QIMR Berghofer Medical Research Institute, Herston, Brisbane, Qld 5Centre for Cancer Research, The University of Sydney at Westmead Millennium Institute, Westmead, NSW 6Bioplatforms Australia, Macquarie University, North Ryde, NSW 7Ludwig Institute for Cancer Research, Olivia Newton-John Cancer and Wellness Centre, Austin Health, Heidelberg, Vic 8The Cancer Development and Treatment Laboratory, Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, The University of Melbourne, Vic 9Departments of Melanoma and Surgical Oncology 10Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia; these authors contributed equally.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAT.0000000000000324DOI Listing
December 2015

Phosphoproteomic Analysis of Cell-Based Resistance to BRAF Inhibitor Therapy in Melanoma.

Front Oncol 2015 15;5:95. Epub 2015 May 15.

Australian Proteome Analysis Facility, Department of Chemistry and Biomolecular Sciences, Macquarie University , Sydney, NSW , Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2015.00095DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4432663PMC
June 2015

Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations.

Sci Rep 2015 Jun 22;5:11198. Epub 2015 Jun 22.

1] Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia [2] Department of Pathology, University of Melbourne, Parkville, Victoria, Australia [3] School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/srep11198DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4476039PMC
June 2015

Low-dose cyclophosphamide enhances antigen-specific CD4(+) T cell responses to NY-ESO-1/ISCOMATRIX™ vaccine in patients with advanced melanoma.

Cancer Immunol Immunother 2015 Apr 7;64(4):507-18. Epub 2015 Feb 7.

Ludwig Institute for Cancer Research (Melbourne-Austin Branch), 147-163 Studley Road, Heidelberg, VIC, 3084, Australia,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-015-1656-xDOI Listing
April 2015

Embryonic Chicken Transplantation is a Promising Model for Studying the Invasive Behavior of Melanoma Cells.

Front Oncol 2015 16;5:36. Epub 2015 Feb 16.

Cancer Immunobiology Laboratory, Ludwig Institute for Cancer Research, Melbourne-Austin Branch , Heidelberg, VIC , Australia ; Department of Medicine, University of Melbourne , Melbourne, VIC , Australia ; School of Cancer Medicine, La Trobe University , Melbourne, VIC , Australia.

View Article

Download full-text PDF

Source
http://journal.frontiersin.org/Article/10.3389/fonc.2015.000
Publisher Site
http://dx.doi.org/10.3389/fonc.2015.00036DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4329807PMC
March 2015

Whole exome sequencing identifies a recurrent RQCD1 P131L mutation in cutaneous melanoma.

Oncotarget 2015 Jan;6(2):1115-27

Division of Cancer Research, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.Department of Pathology, University of Melbourne, Parkville, Victoria, Australia.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359221PMC
http://dx.doi.org/10.18632/oncotarget.2747DOI Listing
January 2015

The role of circulating microRNA in hepatocellular carcinoma.

Front Biosci (Landmark Ed) 2015 Jan 1;20:78-104. Epub 2015 Jan 1.

The University of Melbourne, Department of Surgery Austin Health, Studley Road, Heidelberg, Victoria, Australia 3084.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2741/4299DOI Listing
January 2015

Effects of epithelial to mesenchymal transition on T cell targeting of melanoma cells.

Front Oncol 2014 17;4:367. Epub 2014 Dec 17.

Cancer Immunobiology Laboratory, Ludwig Institute for Cancer Research, Melbourne-Austin Branch, Olivia Newton John Cancer and Wellness Centre , Melbourne, VIC , Australia ; School of Cancer Medicine, La Trobe University , Melbourne, VIC , Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2014.00367DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4269118PMC
January 2015

Clinical and pathological associations of the activating RAC1 P29S mutation in primary cutaneous melanoma.

Pigment Cell Melanoma Res 2014 Nov 4;27(6):1117-25. Epub 2014 Aug 4.

Victorian Melanoma Service, Alfred Hospital, Melbourne, Vic., Australia; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Vic., Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Vic., Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12295DOI Listing
November 2014

Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.

J Clin Oncol 2014 Nov 6;32(33):3697-704. Epub 2014 Oct 6.

Douglas B. Johnson and Jeffrey A. Sosman, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center; Jeffrey R. Infante and Howard A. Burris III, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Keith T. Flaherty and Donald P. Lawrence, Massachusetts General Hospital Cancer Center, Boston MA; Jeffrey S. Weber and Geoffrey T. Gibney, Moffitt Cancer Center, Tampa, FL; Kevin B. Kim and Gerald S. Falchook, University of Texas MD Anderson Cancer Center, Houston, TX; Richard F. Kefford and Georgina V. Long, Melanoma Institute Australia, University of Sydney and Westmead Hospital, Sydney, New South Wales; Jonathan Cebon, Joint Ludwig-Austin Oncology Unit, Austin Health, Melbourne, Victoria, Australia; Omid Hamid, Angeles Clinic and Research Institute, Los Angeles; Alain Algazi and Adil Daud, University of California, San Francisco, San Francisco, CA; Lynn Schuchter, University of Pennsylvania Abramson Cancer Center; Nageatte Ibrahim, Peng Sun, Shonda Little, and Elizabeth Cunningham, GlaxoSmithKline, Philadelphia, PA; William H. Sharfman, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD; Robert R. McWilliams, Mayo Clinic, Rochester, MN; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Karl Lewis and Rene Gonzalez, University of Colorado, Denver, CO; and Kiran Patel, Incyte, Wilmington, DE.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.57.3535DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226803PMC
November 2014

Development of a novel, quantitative protein microarray platform for the multiplexed serological analysis of autoantibodies to cancer-testis antigens.

Int J Cancer 2014 Oct 24;135(8):1842-51. Epub 2014 Mar 24.

Institute of Infectious Disease and Molecular Medicine/Division of Medical Biochemistry, University of Cape Town, Cape Town, South Africa; Biosciences Division, Council for Scientific and Industrial Research, Pretoria, South Africa.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ijc.28832
Publisher Site
http://dx.doi.org/10.1002/ijc.28832DOI Listing
October 2014

Sphingosine-1-phosphate lyase is expressed by CD68+ cells on the parenchymal side of marginal reticular cells in human lymph nodes.

Eur J Immunol 2014 Aug 12;44(8):2425-36. Epub 2014 Jun 12.

School of Biological Sciences, The University of Auckland, Auckland, New Zealand; Maurice Wilkins Centre for Molecular Biodiscovery, The University of Auckland, Auckland, New Zealand.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/eji.201344158
Publisher Site
http://dx.doi.org/10.1002/eji.201344158DOI Listing
August 2014

Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment.

Expert Rev Clin Immunol 2014 Aug 17;10(8):1107-23. Epub 2014 Jun 17.

Ludwig Institute for Cancer Research, Melbourne-Austin Branch, Cancer Immuno-biology Laboratory, Heidelberg, VIC 3084, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/1744666X.2014.929943DOI Listing
August 2014

Thrombospondin 1 promotes an aggressive phenotype through epithelial-to-mesenchymal transition in human melanoma.

Oncotarget 2014 Jul;5(14):5782-97

Ludwig Institute for Cancer Research, Melbourne-Austin Branch, Cancer Immunobiology Laboratory, Heidelberg, VIC 3084, Australia. Department of Medicine, University of Melbourne, Victoria, 3010, Australia.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4170613PMC
http://dx.doi.org/10.18632/oncotarget.2164DOI Listing
July 2014

The kinase inhibitors dabrafenib and trametinib affect isolated immune cell populations.

Oncoimmunology 2014;3(7):e946367. Epub 2014 Jul 3.

Ludwig Institute for Cancer Research; Melbourne-Austin Branch; Cancer Immuno-biology Laboratory ; Heidelberg, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/21624011.2014.946367DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4292757PMC
July 2014

Evolving role of tumor antigens for future melanoma therapies.

Future Oncol 2014 Jun;10(8):1457-68

Ludwig Institute for Cancer Research Ltd, Olivia Newton-John Cancer & Wellness Centre, Cancer Immunobiology, Heidelberg, VIC, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.14.84DOI Listing
June 2014

A single-centre experience of patients with metastatic melanoma enrolled in a dabrafenib named patient programme.

Melanoma Res 2014 Apr;24(2):144-9

aLudwig Institute for Cancer Research - Austin Branch, Joint Ludwig-Austin Medical Oncology Unit, Olivia Newton John Cancer and Wellness Centre, Austin Health bEastern Health Clinical School, Monash University, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000036DOI Listing
April 2014

BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition.

J Clin Oncol 2013 Dec 4;31(35):e448-51. Epub 2013 Nov 4.

Joint Ludwig-Austin Oncology Unit, Austin Health, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.50.4118DOI Listing
December 2013

Intratumoral genetic heterogeneity in metastatic melanoma is accompanied by variation in malignant behaviors.

BMC Med Genomics 2013 Oct 11;6:40. Epub 2013 Oct 11.

Cancer Immuno-biology Lab, Ludwig Institute for Cancer Research Melbourne, Austin Branch, Melbourne, Victoria 3084, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1755-8794-6-40DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3852494PMC
October 2013

Tumor-specific T-cell help is associated with improved survival in melanoma.

Clin Cancer Res 2013 Aug 17;19(15):4021-3. Epub 2013 Jul 17.

Ludwig Institute for Cancer Research Melbourne-Austin Branch, Heidelberg, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-1349DOI Listing
August 2013

Fine-mapping naturally occurring NY-ESO-1 antibody epitopes in melanoma patients' sera using short overlapping peptides and full-length recombinant protein.

Mol Immunol 2013 Jul 27;54(3-4):465-71. Epub 2013 Feb 27.

Ludwig Institute for Cancer Research Melbourne-Austin Branch, Heidelberg, VIC 3084, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molimm.2013.01.014DOI Listing
July 2013

The Ludwig institute for cancer research Melbourne melanoma cell line panel.

Pigment Cell Melanoma Res 2013 Jul 11;26(4):597-600. Epub 2013 Apr 11.

Ludwig Institute for Cancer Research, Austin Hospital Level 5, Olivia Newton-John Cancer & Wellness Centre, Heidelberg, Vic., Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12097DOI Listing
July 2013

Human perforin mutations and susceptibility to multiple primary cancers.

Oncoimmunology 2013 Apr;2(4):e24185

Cancer Immunology Program; Peter MacCallum Cancer Institute; East Melbourne, VIC Australia; and Sir Peter MacCallum Department of Oncology; The University of Melbourne; Melbourne, VIC Australia ; Research Division; Peter MacCallum Cancer Centre; East Melbourne, VIC Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/onci.24185DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654607PMC
April 2013

Inhibitor of apoptosis protein (IAP) antagonists demonstrate divergent immunomodulatory properties in human immune subsets with implications for combination therapy.

Cancer Immunol Immunother 2013 Feb 26;62(2):321-35. Epub 2012 Aug 26.

Ludwig Institute for Cancer Research Melbourne, Austin Branch, Austin Hospital, 145-163 Studley Road, Heidelberg, VIC, 3084, Australia.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00262-012-1342-1
Publisher Site
http://dx.doi.org/10.1007/s00262-012-1342-1DOI Listing
February 2013

Flt3 ligand expands CD4+ FoxP3+ regulatory T cells in human subjects.

Eur J Immunol 2013 Feb 5;43(2):533-9. Epub 2012 Dec 5.

Ludwig Institute for Cancer Research, Melbourne Centre for Clinical Sciences, Heidelberg, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/eji.201242603DOI Listing
February 2013

FOXP3 is not mutated in human melanoma.

Pigment Cell Melanoma Res 2012 May 16;25(3):398-400. Epub 2012 Mar 16.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1755-148X.2012.00993.xDOI Listing
May 2012

A novel method for detecting antigen-specific human regulatory T cells.

J Immunol Methods 2012 Mar 13;377(1-2):56-61. Epub 2012 Jan 13.

Ludwig Institute for Cancer Research (Melbourne-Austin Branch), Melbourne, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jim.2012.01.004DOI Listing
March 2012

Stem cell media culture of melanoma results in the induction of a nonrepresentative neural expression profile.

Stem Cells 2012 Feb;30(2):336-43

Cancer Immuno-biology Lab, Ludwig Institute for Cancer Research, Melbourne-Austin Branch, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/stem.786
Publisher Site
http://dx.doi.org/10.1002/stem.786DOI Listing
February 2012

The Ets transcription factor ELF5 functions as a tumor suppressor in the kidney.

Twin Res Hum Genet 2011 Aug;14(4):316-22

Centre for Functional Genomics and Human Disease, Monash Institute of Medical Research, Monash University, Australia.

View Article

Download full-text PDF

Source
http://www.journals.cambridge.org/abstract_S1832427400011518
Publisher Site
http://dx.doi.org/10.1375/twin.14.4.316DOI Listing
August 2011

Melanoma vaccines: developments over the past 10 years.

Expert Rev Vaccines 2011 Jun;10(6):853-73

Ludwig Institute for Cancer Research, Austin Branch, Austin Hospital, Studley Road, Heidelberg, Victoria, 3084, Australia.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.1586/erv.11.74
Publisher Site
http://dx.doi.org/10.1586/erv.11.74DOI Listing
June 2011

Cancer stem cells in urologic cancers.

Urol Oncol 2010 Nov-Dec;28(6):585-90. Epub 2009 Nov 7.

Department of Medicine, Melbourne University, Austin Health, Studley Road, Heidelberg, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2009.06.010DOI Listing
February 2011

Influenza A infection enhances cross-priming of CD8+ T cells to cell-associated antigens in a TLR7- and type I IFN-dependent fashion.

J Immunol 2010 Nov 18;185(10):6013-22. Epub 2010 Oct 18.

Ludwig Institute for Cancer Research, Austin Health, Heidelberg, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.1002129DOI Listing
November 2010

Processing and cross-presentation of individual HLA-A, -B, or -C epitopes from NY-ESO-1 or an HLA-A epitope for Melan-A differ according to the mode of antigen delivery.

Blood 2010 Jul 29;116(2):218-25. Epub 2010 Apr 29.

Ludwig Institute for Cancer Research, Centre for Clinical Sciences, Austin Health, Melbourne, VIC 3084, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2009-10-249458DOI Listing
July 2010

Evaluation of cellular immune responses in cancer vaccine recipients: lessons from NY-ESO-1.

Expert Rev Vaccines 2010 Jun;9(6):617-29

Ludwig Institute for Cancer Research, Austin Hospital, Heidelberg VIC 3084, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/erv.10.58DOI Listing
June 2010

Cancer vaccines: Where are we going?

Authors:
Jonathan Cebon

Asia Pac J Clin Oncol 2010 Mar;6 Suppl 1:S9-15

Austin Ludwig Oncology Unit, Ludwig Institute, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1743-7563.2010.01270.xDOI Listing
March 2010

Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells.

Cancer Immunol Immunother 2009 Oct 17;58(10):1635-46. Epub 2009 Feb 17.

Ludwig Institute for Cancer Research, Austin Hospital, Studley Road, Heidelberg, VIC, 3084, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-009-0672-0DOI Listing
October 2009

Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma.

Clin Cancer Res 2009 Mar 10;15(6):2166-73. Epub 2009 Mar 10.

Ludwig Institute for Cancer Research, Austin Health, Peter MacCallum Cancer Centre, CSL Limited, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-08-2484DOI Listing
March 2009